曼金德制药公司获得在印度销售罗氏Rivotril的权利, 以扩大其中枢神经系统药物组合. Mankind Pharma acquires rights to sell Roche’s Rivotril in India to expand its CNS drug portfolio.

曼凯德制药公司获得了在印度市场上销售,生产和分发罗氏Rivotril (克洛纳泽) 的独家权利. Mankind Pharma has acquired exclusive rights to market, manufacture, and distribute Roche’s Rivotril (clonazepam) in India, strengthening its position in the central nervous system therapy area. 这一举动支持公司通过在许可和新产品推出扩大其专业和慢性疾病组合的战略. The move supports the company’s strategy to expand its specialty and chronic disease portfolio through in-licensing and new product launches. 人类计划利用超过50万名医生的网络和全国的分销系统, 增加药物获取率并探索潜在产品扩展. Mankind plans to use its network of over 500,000 doctors and nationwide distribution system to increase access to the drug and explore potential product extensions.